Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | PADOVA study: prasinezumab in patients with early Parkinson’s disease

Tania Nikolcheva, MD, PhD, Global Development Leader Prasinezumab, Roche, Basel, Switzerland, discusses the rationale, design, and baseline data of the PADOVA trial (NCT04777331) evaluating the efficacy and safety of intravenous prasinezumab in participants with early Parkinson’s disease. The study builds upon the PASADENA study (NCT03100149) but includes patients who have been treated with levodopa in addition to those who were treatment-naive or treated with type-B monoamine oxidase inhibitors. The study’s primary endpoint is time to confirmed motor progression event, specifically the appearance of meaningful motor progression defined as a five-point increase on the MDS-UPDRS scale. Dr Nikolcheva compares the baseline data from the PADOVA study to the PASADENA and PPMI studies, noting slight differences in patient characteristics. The results of this study will help determine the impact of prasinezumab on PD progression. If successful, the study may pave the way for Phase III trials. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr Nikolcheva is a full-time employee and shareholder at F. Hoffmann – La Roche Ldt.